MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 75 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,463,328 | -24.4% | 430,227 | +2.0% | 0.00% | 0.0% |
| Q2 2023 | $4,581,226 | +758.4% | 421,844 | +445.4% | 0.00% | – |
| Q1 2023 | $533,667 | +76.3% | 77,343 | +1.7% | 0.00% | – |
| Q4 2022 | $302,786 | -20.3% | 76,077 | +33.5% | 0.00% | – |
| Q3 2022 | $380,000 | +37.2% | 57,003 | -0.1% | 0.00% | – |
| Q2 2022 | $277,000 | -90.7% | 57,083 | -82.1% | 0.00% | -100.0% |
| Q1 2022 | $2,978,000 | -25.1% | 318,577 | -4.9% | 0.00% | 0.0% |
| Q4 2021 | $3,978,000 | +3.5% | 334,910 | -0.9% | 0.00% | 0.0% |
| Q3 2021 | $3,845,000 | -40.7% | 337,801 | -6.5% | 0.00% | 0.0% |
| Q2 2021 | $6,483,000 | +34.1% | 361,393 | +15.7% | 0.00% | 0.0% |
| Q1 2021 | $4,833,000 | +38.3% | 312,221 | +9.0% | 0.00% | 0.0% |
| Q4 2020 | $3,494,000 | -4.0% | 286,398 | +1.2% | 0.00% | 0.0% |
| Q3 2020 | $3,638,000 | – | 283,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |